PSNL (Personalis) Return-on-Tangible-Equity: -46.57% (As of Mar. 2026)


PSNL Personalis Inc PSNL
60 GF Score
Price $13.62
GF Value $2.07
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Personalis Return-on-Tangible-Equity?

Personalis PSNL -1.30% 60 Return-on-Tangible-Equity is -46.57% as of Mar. 2026. GuruFocus rates PSNL with a GF Score™ of 60/100 and a GF Value™ of $2.07 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 192 Medical Diagnostics & Research companies, Personalis ranks worse than 75% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Personalis's annualized net income for the quarter that ended in Mar. 2026 was $-120.13 Mil. Personalis's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $257.98 Mil. Therefore, Personalis's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -46.57%.

The historical rank and industry rank for Personalis's Return-on-Tangible-Equity or its related term are showing as below:

PSNL' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -16611.92   Med: -42.89   Max: -25.82
Current: -44.01

During the past 9 years, Personalis's highest Return-on-Tangible-Equity was -25.82%. The lowest was -16,611.92%. And the median was -42.89%.

PSNL's Return-on-Tangible-Equity is ranked worse than
75% of 192 companies
in the Medical Diagnostics & Research industry
Industry Median: -0.405 vs PSNL: -44.01

Personalis  (NAS:PSNL) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Personalis Return-on-Tangible-Equity Related Terms


Personalis Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Personalis's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Personalis Return-on-Tangible-Equity Chart

Personalis Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only -25.82 -42.89 -62.31 -48.91 -35.02

Personalis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.71 -40.30 -47.82 -44.04 -46.57

PSNL vs CDNA, OPK, NEO: Return-on-Tangible-Equity Comparison

For the Diagnostics & Research subindustry, Personalis's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Personalis Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Personalis's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Personalis's Return-on-Tangible-Equity falls into.


PSNL
60GF Score
Personalis Inc PSNL
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Personalis Return-on-Tangible-Equity Calculation

Personalis's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-81.27/( (202.957+261.185 )/ 2 )
=-81.27/232.071
=-35.02 %

Personalis's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-120.128/( (261.185+254.765)/ 2 )
=-120.128/257.975
=-46.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of -46.57% mean?
Personalis (PSNL) has a Return-on-Tangible-Equity of -46.57% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Personalis and its competitors. According to the industry distribution chart, Personalis ranks #144 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 75%.
Is Personalis' Return-on-Tangible-Equity too high?
Personalis' current Return-on-Tangible-Equity is -46.57%. Based on the distribution chart, Personalis ranks #144 out of 192 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Personalis has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Personalis' Return-on-Tangible-Equity compare to CDNA and OPK?
According to the Medical Diagnostics & Research industry distribution chart, Personalis ranks #144 out of 192 companies for Return-on-Tangible-Equity. This places Personalis in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Personalis and its competitors. Personalis's current Return-on-Tangible-Equity is -46.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Personalis stock overvalued right now?
Based on GuruFocus' analysis, Personalis (PSNL) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.07, compared to a current price of $13.62 — trading 558% above its estimated fair value. The current Return-on-Tangible-Equity is -46.57%. Personalis' overall GF Score™ is 60/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Personalis (PSNL), the current Return-on-Tangible-Equity is -46.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Personalis (PSNL) Overvalued in 2026?

Based on GuruFocus' analysis, Personalis stock appears to be overvalued. The current stock price of $13.62 is trading 558% above its estimated GF Value™ of $2.07. GuruFocus considers Personalis to be Significantly Overvalued.

Key valuation signals for PSNL:

  • Return-on-Tangible-Equity: -46.57%
  • GF Value™: $2.07 vs. price of $13.62 (558% above fair value)
  • GF Score™: 60/100 with 9 warning signs

No single metric tells the full story. See the PSNL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Personalis Business Description

Other Exchanges 04X:Germany
Address 6600 Dumbarton Circle, Fremont, CA, USA, 94555
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
60GF Score

Get the complete analysis for PSNL

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.62
Price
$2.07
GF Value